🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

642 results for “Pharma Mar S.A.” Clear

  1. CRD-4730, Encapsulation of microcrystalline cellulose into HPMC capsules to match the CRD-4730 active capsules in appearance

    Pharma Mar S.A.

    Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

    phase 2 small molecule active

    1 trial

  2. CX11, Placebo to cx11 40 mg, CX11, Placebo to cx11 80 mg

    Pharma Mar S.A.

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  3. Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules

    Pharma Mar S.A.

    Relapsed/Refractory marginal zone lymphoma

    phase 2 small molecule active

    1 trial

  4. Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules

    Pharma Mar S.A.

    Waldenström Macroglobulinemia

    phase 2 small molecule active

    1 trial

  5. Calquence 100 mg hard capsules, Calquence 100 mg film-coated tablets

    Pharma Mar S.A.

    Richter's Syndrome, Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  6. Calquence 100 mg hard capsules, Calquence 100 mg film-coated tablets

    Pharma Mar S.A.

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  7. Calquence 100 mg hard capsules, IMBRUVICA 420 mg film-coated tablets, IMBRUVICA 140 mg hard capsules, IMBRUVICA 140 mg hard capsules, BRUKINSA 80 mg hard capsules, Lisaftoclax, Calquence 100 mg hard capsules, MabThera 500 mg concentrate for solution for infusion, Lisaftoclax, Lisaftoclax

    Pharma Mar S.A.

    Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

    phase 2 small molecule active

    1 trial

  8. Cemiplimab and Fianlimab - 1, Fianlimab, Cemiplimab & Fianlimab - 2, LIBTAYO 350 mg concentrate for solution for infusion., Placebo for Fianlimab

    Pharma Mar S.A.

    Melanoma

    phase 2 small molecule active

    1 trial

  9. Cemiplimab and Fianlimab - 1, Placebo, LIBTAYO 350 mg concentrate for solution for infusion., PEMETREXED, CARBOPLATIN, CISPLATIN, Cemiplimab & Fianlimab - 2, PACLITAXEL

    Pharma Mar S.A.

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. Chlorid sodný B. Braun 0,9 % infuzní roztok, DUOFAG

    Pharma Mar S.A.

    Surgical wound infection/dehiscence caused by S. aureus and/or P. aeruginosa colonization

    phase 2 small molecule active

    1 trial

  11. Citanest® Dental Octapressin 30 mg/ml + 0,03 IE/ml, Xylocain ®Dental adrenalin 20 mg/ml + 12,5 mikrog/ml Injeksjonsvæske, oppløsning i sylindretter

    Pharma Mar S.A.

    Subjects having local anesthesia for dental procedures.

    phase 2 small molecule active

    1 trial

  12. Cizutamig

    Pharma Mar S.A.

    Severe, treatment refractory primary Sjögren’s disease (pSjD), Severe, treatment refractory idiopathic inflammatory myopathy (IIM), Severe, treatment refractory systemic sclerosis (SSc), Severe, treatment-refractory, seropositive (anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor positive) rheumatoid arthritis (RA)

    phase 2 small molecule active

    1 trial

  13. Crofelemer Placebo Powder for Oral Solution

    Pharma Mar S.A.

    Microvillous Inclusion Disease (MVID)

    phase 2 small molecule active

    1 trial

  14. DB-OTO

    Pharma Mar S.A.

    Congenital Hearing Loss Secondary to Biallelic Pathogenic Variants of the Otoferlin Gene (OTOF)

    phase 2 small molecule active

    1 trial

  15. DCC-3014, DCC-3014, DCC-3014

    Pharma Mar S.A.

    Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

    phase 2 small molecule active

    1 trial

  16. DCC-3084, DCC-3084

    Pharma Mar S.A.

    Solid tumors driven by the MAPK Pathway

    phase 2 small molecule active

    1 trial

  17. DNS-6288, DNS-6288

    Pharma Mar S.A.

    Catecholaminergic Polymorphic Ventricular Tachycardia

    phase 2 small molecule active

    1 trial

  18. Dantrolene sodium semiheptahydrate, SODIUM CHLORIDE, VISTABEL 4 Allergan-Einheiten/0,1 ml Pulver zur Herstellung einer Injektionslösung, FTP-002/FTP-501 combination

    Pharma Mar S.A.

    glabellar lines.

    phase 2 small molecule active

    1 trial

  19. Daridorexant matching placebo, QUVIVIQ 50 mg film-coated tablets, QUVIVIQ 25 mg film-coated tablets

    Pharma Mar S.A.

    Insomnia Disorder

    phase 2 small molecule active

    1 trial

  20. Dexamethasone 4 mg tablets, Cytarabine 20 mg/ml Solution for Injection or Infusion, Calquence 100 mg hard capsules, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Histergan Tablets, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, Mesna Injection, Methylprednisolone 1000 mg powder and solvent for solution for injection/infusion, RoActemra 20 mg/mL concentrate for solution for infusion, Panadol 50

    Pharma Mar S.A.

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  21. Dexamethasone phosphate 4 mg/ml solution for injection/infusion, Paracetamol 500 mg Film-Coated Tablets, Diluent for REGN5458, Linvoseltamab, Diphenhydramine Hydrochloride 25 mg Tablets, Dermodrin 30 mg/2 ml soluție injectabilă, Dexamethasone 4 mg tablets, RoActemra 20 mg/mL concentrate for solution for infusion, Linvoseltamab

    Pharma Mar S.A.

    Relapsed or Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  22. Diagnóstico prick Dermatophagoides farinae 40 HEP/ml, Diagnóstico prick control positivo, Diagnóstico prick Dermatophagoides pteronyssinus 40 HEP/ml, Diagnóstico prick control negativo

    Pharma Mar S.A.

    Allergies

    phase 2 small molecule active

    1 trial

  23. Diagnóstico prick control positivo, Diagnóstico prick Olea Europae, Diagnóstico prick control negativo, Diagnóstico prick Olea Europae, Diagnóstico prick Olea Europae, Diagnóstico prick Olea Europae

    Pharma Mar S.A.

    Allergies

    phase 2 small molecule active

    1 trial

  24. Diagnóstico prick control positivo, Dignostico prick Blomia tropicalis, Diagnóstico prick Blomia tropicalis, Diagnóstico prick Blomia tropicalis, Diagnóstico prick Blomia tropicalis, Diagnóstico prick control negativo

    Pharma Mar S.A.

    Allergies

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources